Regado Biosciences develops antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 17, 2012 | Series E | $51M | 1 | — | — | Detail |
Dec 17, 2009 | Series D | $40M | 1 | — | — | Detail |
Mar 27, 2007 | Series C | $23M | 1 | Caxton Advantage Life Sciences Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Caxton Advantage Life Sciences Fund | — | Series E |